论文部分内容阅读
目的:本实验方法是通过观测瑞舒伐他汀在高脂血症患者体内对血脂纤溶酶原激活物抑制剂的影响,来研究他汀类药物对高血脂患者的降脂作用。方法:将治疗前患者的纤溶酶原激活物抑制剂和白细胞介素浓度准确记录;给患者使用他汀类药物6周;对前述指标再次进行测量。结果:数据显示,患者使用他汀类药物后,其体内的TC和LDL都明显降低,其中TC降低幅度为28.41%,TG降低幅度为37.64%,与此同时,多数患者的HDL浓度不降反升。结论:他汀类药物具有明显的调节脂血的功能,并拥有令人满意的消炎作用且能够对纤溶系统的活性产生积极影响。
OBJECTIVE: The experimental method is to study the lipid-lowering effect of statins on hyperlipidemia patients by observing the effect of rosuvastatin on plasma lipid plasminogen activator inhibitor in patients with hyperlipidemia. Methods: Pretreatment patients with plasminogen activator inhibitor and interleukin concentrations accurately recorded; patients with statins for 6 weeks; the above indicators were measured again. Results: The data showed that the TC and LDL in patients after statins were significantly decreased, TC decreased 28.41%, TG decreased 37.64%, while the majority of patients with HDL concentration did not fall . Conclusions: Statins have a clear lipid-lipid-modulating function and have a satisfactory anti-inflammatory effect and can have a positive effect on fibrinolytic system activity.